Fenofibrate
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fenofibrate and local guidelines before prescribing.
Fibrate
Mechanism
PPAR-alpha agonist.
Uses
Hypertriglyceridaemia, mixed dyslipidaemia, diabetic retinopathy (selected).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
GI upset, myopathy, raised creatinine, gallstones.
Interactions
Statins increase myopathy; warfarin effect rises.
Contraindications and cautions
Severe renal or liver impairment, gallbladder disease
Monitoring
Lipids, LFT, CK if symptoms
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in moderate to severe renal impairment
Overdose and reversal
Supportive
Special advice
Check creatinine; not first-line for LDL.
More from the textbook: uses, cautions and other points
- Fibrates (fenofibrate) - mainly lower triglycerides; myopathy risk with statins.
Cardiology: Anatomy Physiology and Pharmacology - Fibrates (e.g. fenofibrate) and omega-3 for very high triglycerides to prevent pancreatitis.
Endocrinology: Lipids and obesity - Fenofibrate | For very high triglycerides (pancreatitis risk). Not routine CV prevention.
Endocrinology: Lipids and obesity - Drugs raising creatinine without reducing GFR - trimethoprim, cimetidine (block tubular secretion); fenofibrate.
Biochemistry: Clinical biochemistry - interpreting laboratory tests
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Lipids and obesity (2 mentions)
- Biochemistry: Clinical biochemistry - interpreting laboratory tests (1 mention)